Home > Healthcare > Medical Devices > Diagnostic Devices > oncology based molecular diagnostics market
Get a free sample of Oncology Based Molecular Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Oncology Based Molecular Diagnostics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The oncology based molecular diagnostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the oncology based molecular diagnostics industry include:
Oncology based molecular diagnostics market size was USD 2.2 billion in 2023 and is expected to reach over USD 3.3 billion by 2032 owing to the rising cases of cancer from population aging, lifestyle changes, and the rising prevalence of risk factors such as smoking and obesity worldwide.
The reagents and kits segment is expected to reach USD 2 billion by 2032 due to reagents and kits being indispensable components for molecular diagnostic assays.
Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann La Roche Ltd., Hologic, Inc., Illumina, Inc., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc., are some of the major oncology based molecular diagnostics companies worldwide.
North America oncology based molecular diagnostics industry recorded 40.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to high prevalence of cancer in the region.